06:15:12 EST Wed 20 Nov 2019
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Shell Summary for Oct. 17, 2019

2019-10-17 22:35 ET - Market Summary

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The TSX Venture Exchange gained 5.02 points to close at 544.07 Thursday. Doron Cohen's second capital pool shell, A-Labs Capital II Corp. (ALAB: halted), plans to acquire an Israeli company called S.R.P. Plus Holdings Ltd. for the shell's qualifying transaction. The full terms of the QT are not yet available, but shareholders of A-Labs Capital II are expected to own 2.4 per cent of the resulting issuer's shares on closing of the QT, while shareholders of S.R.P. Plus are expected to own 73.2 per cent. The remaining 24.4 per cent will then be owned by the subscribers to a proposed financing. Assuming no rollback, these percentages mean that the shell, which has 5.7 million shares issued, will issue 173.85 million shares to its target's shareholders.

S.R.P. Plus bills itself as a commercial real estate company with a focus on managing and renting out medical centres. It is unclear whether the company is already operating this commercial leasing business or if this is but an ambition at the moment. The company does operate a chain of four medical clinics in Israel. Each of them is called VLife Center. Two more VLife Center clinics are on the way (also in Israel). S.R.P. Plus refers to its VLife Center locations as "pain management and aesthetics clinics." They started out as skin care clinics, offering facial treatments and other anti-aging procedures. As for the "cannabinoid-based pain management" treatments, these appear to be a recent and trendy addition.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2019 Canjex Publishing Ltd. All rights reserved.


Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.